Zepbound works differently from Ozempic. That one difference is why it produces 47% more weight loss in head-to-head trials.
🔑 Key Takeaways
- Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist. It activates two gut hormone receptors instead of one, which is why it outperforms every single-receptor weight loss drug
- The GLP-1 component suppresses appetite and slows digestion (same as Ozempic). The GIP component adds direct fat tissue metabolism, better insulin sensitivity, and may preserve more muscle during weight loss
- In the SURMOUNT-5 head-to-head trial, Zepbound produced 20.2% body weight loss vs 13.7% for Wegovy (semaglutide), a 47% improvement
- Zepbound is FDA-approved for weight loss in adults with BMI 30+ or BMI 27+ with a weight-related condition. Also approved for obstructive sleep apnea.
- Same molecule as Mounjaro (approved for type 2 diabetes). Different brand name, different approved use, identical drug
- Side effects are primarily gastrointestinal (nausea, diarrhea, constipation) and actually milder than Wegovy despite producing more weight loss
Below is exactly how Zepbound works in your body, why the dual mechanism matters, what the clinical data shows, and what to expect.
How Zepbound Works: The Dual Mechanism
Two hormone receptors, not one.
Every weight loss injection on the market works through GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating. GLP-1 suppresses appetite, slows digestion, and helps regulate blood sugar. Ozempic and Wegovy activate this one receptor.
Zepbound activates two: GLP-1 AND GIP (glucose-dependent insulinotropic polypeptide). That second receptor is what makes the difference.
What GLP-1 Does (the shared mechanism)
- Appetite suppression: GLP-1 receptors in the hypothalamus and brainstem reduce hunger signals. Most people describe "food noise" disappearing, the constant mental background of thinking about food goes quiet.
- Slowed gastric emptying: Food sits in the stomach longer, extending fullness after meals. This is also why nausea is a common side effect.
- Blood sugar regulation: GLP-1 stimulates insulin release and suppresses glucagon, improving blood sugar control.
What GIP Adds (what makes Zepbound different)
GIP receptors are found in fat tissue, muscle, bone, and the brain. When Zepbound activates them:
- Direct fat metabolism: GIP receptors in adipose tissue change how fat cells process and release stored energy. You don't just eat less, your body handles existing fat differently.
- Better insulin sensitivity: GIP improves insulin response through pathways that GLP-1 alone doesn't reach. This produces the largest A1c reductions of any injectable diabetes medication.
- Muscle preservation: GIP receptors are expressed in muscle tissue. Emerging data suggests GIP signaling reduces muscle protein breakdown during weight loss, meaning you keep more lean mass.
- Reduced GI side effects: The GIP component appears to buffer the nausea that GLP-1 activation causes. This likely explains why Zepbound has lower nausea and vomiting rates than Wegovy.
The simple version
Wegovy (semaglutide) primarily makes you eat less. Zepbound makes you eat less AND changes how your body processes stored fat. Two levers instead of one. That's why the weight loss gap is 47%, not 5%.
How Much Weight Do You Lose on Zepbound?
The trial data is clear.
| Trial | Dose | Average Weight Loss | % Who Lost 20%+ |
|---|---|---|---|
| SURMOUNT-1 | 5mg | -15.0% | 30.0% |
| SURMOUNT-1 | 10mg | -19.5% | 50.1% |
| SURMOUNT-1 | 15mg | -20.9% | 56.7% |
| SURMOUNT-5 (vs Wegovy) | 10-15mg | -20.2% (vs -13.7%) | 51.6% (vs 31.5%) |
At the highest dose, more than half of people lost 20% or more of their body weight. For someone starting at 250 lbs, that's 50+ lbs. The placebo group in these trials lost about 3%, showing the magnitude of the drug effect.
Source: Jastreboff et al. NEJM 2022 (SURMOUNT-1); NEJM 2025 (SURMOUNT-5). Full trial data on the clinical trial reference page.
Zepbound vs Wegovy: Why Zepbound Works Better
| Feature | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Receptors | GLP-1 + GIP (dual) | GLP-1 only (single) |
| Average weight loss (max dose) | ~21% | ~15% |
| Head-to-head (SURMOUNT-5) | 20.2% | 13.7% |
| Nausea rate | ~28% | ~44% |
| Vomiting rate | ~13% | ~25% |
| CV outcome data | Under review | SELECT: 20% MACE reduction |
| Sleep apnea approval | Yes (SURMOUNT-OSA) | No |
| Cost (branded) | ~$1,060/month | ~$1,350/month |
Zepbound wins on weight loss, GI tolerability, and price. Wegovy wins on cardiovascular outcome data (SELECT trial showed 20% reduction in heart attacks and strokes). If you have heart disease, that matters. For most people focused on weight loss, Zepbound is the stronger choice. Full comparison on the tirzepatide vs semaglutide page.
How Zepbound Is Taken
Once a week, same day each week.
Zepbound is injected subcutaneously (under the skin) using a pre-filled pen. Inject in the abdomen, thigh, or upper arm. Rotate injection sites. You can take it at any time of day, with or without food.
Dosing Schedule
| Phase | Dose | Duration |
|---|---|---|
| Starting | 2.5mg weekly | 4 weeks |
| Step 2 | 5mg weekly | 4 weeks |
| Step 3 | 7.5mg weekly | 4 weeks |
| Step 4 | 10mg weekly | 4 weeks |
| Step 5 | 12.5mg weekly | 4 weeks |
| Maximum | 15mg weekly | Ongoing |
The 2.5mg starting dose is for GI adaptation only, not expected to produce significant weight loss. Each step up may temporarily bring back GI side effects as the body adjusts. Many people find their optimal dose at 10mg or 12.5mg rather than pushing to 15mg. If nausea is significant at any step, hold for an extra 4 weeks before increasing.
Full dosing details on the tirzepatide dosage page.
Side Effects of Zepbound
Milder than Wegovy despite stronger results.
| Side effect | Zepbound (15mg) | When it peaks | Management |
|---|---|---|---|
| Nausea | ~28% | First 2-4 weeks at each dose | Inject at night, smaller meals |
| Diarrhea | ~23% | Weeks 1-4 | Hydration, electrolytes |
| Constipation | ~11% | Variable | Fiber, magnesium, 2L+ water |
| Vomiting | ~13% | During dose escalation | Slow titration |
| Injection site reactions | Low | 24-72 hours | Rotate sites |
Serious but rare: pancreatitis (<1%), gallbladder disease (1-3%), thyroid C-cell tumors (FDA black box warning, no confirmed human signal). Contraindicated during pregnancy. Full breakdown on the tirzepatide side effects page.
What Zepbound Is Approved For
- Weight loss: Adults with BMI 30+ or BMI 27+ with at least one weight-related condition (high blood pressure, high cholesterol, T2D, etc.)
- Obstructive sleep apnea: Adults with moderate-to-severe OSA and larger body size (SURMOUNT-OSA showed up to 63% reduction in sleep apnea severity)
Zepbound is NOT approved for type 2 diabetes. Mounjaro is the tirzepatide brand for diabetes. Same molecule, different label.
How to Get Zepbound
| Option | Monthly cost | Notes |
|---|---|---|
| Zepbound (branded, with insurance) | Varies by plan | Check formulary, copay card available |
| Zepbound (branded, cash pay) | ~$1,060 | Eli Lilly savings program may apply |
| Compounded tirzepatide | $150-$350 | Same molecule, limited availability |
| Telehealth platform | $200-$500 | Includes consultation + medication |
For the full access landscape, see the GLP-1 without insurance page.
Frequently Asked Questions
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Zepbound is a prescription medication. Consult a licensed healthcare provider to determine if it's appropriate for you.